M&T Bank Corp Buys 10,350 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• M&T Bank Corp raised its stake in Regeneron by 193.9%, buying 10,350 shares to own 15,689 shares worth about $12.11 million per its latest SEC filing.
• Regeneron got major positive catalysts — including FDA approval of the gene therapy Otarmeni and three‑year tariff relief — and several analysts boosted price targets, though the company will provide Otarmeni free to eligible U.S. patients which could limit near‑term revenue.
• The company beat Q4 EPS estimates ($11.44 vs. $10.74), raised its quarterly dividend to $0.94 (annualized $3.76, yield ~0.5%), and holds a consensus rating of “Moderate Buy” with an average price target around $818.

M&T Bank Corp lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 193.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 15,689 shares of the biopharmaceutical company's stock after acquiring an additional 10,350 shares during the period. M&T Bank Corp's holdings in Regeneron Pharmaceuticals were worth $12,110,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Dodge & Cox raised its position in Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company's stock worth $2,558,804,000 after purchasing an additional 724,562 shares during the period. Franklin Resources Inc. raised its position in Regeneron Pharmaceuticals by 6.0% in the 3rd quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company's stock worth $1,379,329,000 after purchasing an additional 139,647 shares during the period. Capital World Investors raised its position in Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company's stock worth $1,123,609,000 after purchasing an additional 32,348 shares during the period. Invesco Ltd. raised its position in Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company's stock worth $834,675,000 after purchasing an additional 408,649 shares during the period. Finally, Northern Trust Corp raised its position in Regeneron Pharmaceuticals by 2.7% in the 3rd quarter. Northern Trust Corp now owns 984,792 shares of the biopharmaceutical company's stock worth $553,719,000 after purchasing an additional 26,223 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company's stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,774 shares of company stock valued at $2,942,738. Insiders own 7.02% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on REGN. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Oppenheimer reissued an "outperform" rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Barclays initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an "overweight" rating and a $923.00 target price on the stock. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 8th. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a "sector perform" rating in a report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $818.13.

Regeneron Pharmaceuticals Stock Up 2.6%

Shares of REGN stock opened at $766.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The stock has a market cap of $80.98 billion, a P/E ratio of 18.43, a P/E/G ratio of 1.66 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a 50 day simple moving average of $763.87 and a two-hundred day simple moving average of $729.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts' consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the company earned $12.07 earnings per share. The firm's revenue was up 2.5% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.05%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni, the first gene therapy to restore hearing — a clear pipeline win that validates Regeneron’s genetic‑medicine platform and de‑risks future revenue streams tied to novel products. Read More.
• Positive Sentiment: Regulatory and clinical data look strong — trial results cited high responder rates (e.g., CHORD trial outcomes reported), supporting commercial potential and positive sentiment around commercialization prospects. Read More.
• Positive Sentiment: Company secured tariff relief under the White House agreement (three years) — a near‑term margin/cost benefit that investors view favorably. Read More.
• Positive Sentiment: Analyst support/upgrades — TD Cowen raised its price target (to $960) and Cantor Fitzgerald reaffirmed “overweight,” reinforcing buy-side conviction and likely contributing to demand. Read More.
• Positive Sentiment: Dupixent label expansions (U.S./EU pediatric approvals) add incremental, low‑risk revenue upside and diversify near‑term growth drivers beyond gene therapy. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major PR/ access move that increases goodwill and access but reduces near‑term product revenue in the U.S.; it may help uptake and market positioning internationally. Read More.
• Negative Sentiment: The agreement includes offering prescriptions at “most‑favored‑nation” prices for some Americans — this could compress pricing and long‑run revenue/margins if broadly applied. Read More.
• Negative Sentiment: Sector weakness: broader health‑care stocks were lower in afternoon trading, which can cap upside even with company‑specific news. Read More.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.